NORTHWELL HEALTH

Health care HR leaders face talent shortages, retention, and burnout, using tech to streamline hiring and engagement. They aim to boost efficiency, support staff, and adapt to evolving health care needs, emphasizing empathy, diversity, and inclusion for better patient outcomes.

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) for routine prophylaxis in hemophilia A or B without inhibitors, making it the first anti-TFPI available in the U.S. for this indication. Hympavzi offers a once-weekly subcutaneous dosing via a pre-filled auto-injector pen. The approval was based on the BASIS trial, showing a 35% reduction in annualized bleeding rates compared to routine prophylaxis and on-demand treatment. Common adverse events were manageable.

FDA approves marstacimab-hncq (Hympavzi; Pfizer) for hemophilia A or B without inhibitors, offering a once-weekly subcutaneous treatment. This is the first anti-tissue factor pathway inhibitor and the first hemophilia treatment administered via a pre-filled auto-injector pen in the US. The approval is based on the phase 3 BASIS trial, showing a 35% reduction in annualized bleeding rate (ABR) for treated bleeds compared to routine prophylaxis and on-demand treatment.

FDA approves marstacimab, an anti-TFPI for hemophilia A and B, reducing bleeding episodes. Hympavzi, by Pfizer, is the first subcutaneous option for hemophilia B, administered weekly via autoinjector. The approval is based on the phase 3 BASIS trial, showing significant reduction in annualized bleeding rates and manageable safety profile.

The FDA approved marstacimab-hncq (Hympavzi, Pfizer) for routine prophylaxis to prevent bleeding episodes in adults and children aged 12+ with hemophilia A or B without inhibitors. It is the first anti-tissue factor pathway inhibitor in the U.S. for such treatment, administered subcutaneously once weekly, and showed significant reduction in annualized bleeding rates in the BASIS trial.

Christina Brennan, MD, advocates for integrating clinical trials into clinical care to enhance patient-centricity, suggesting EMRs and community provider involvement. She highlights the need for career awareness in clinical research and addresses the challenges faced by CRCs, emphasizing the importance of patient choice and real-time data to improve trial experiences.

Dan Schell attended Veeva's R&D and Quality summit in Boston, finding it informative with valuable networking and insights on clinical trial challenges, eCOA readiness, and site data issues. He also met fellow editors, broadening his professional connections.

CCR West celebrates its 40th anniversary with a focus on CAR T-cell therapy and precision medicine, featuring cutting-edge research and presentations by leading experts in rheumatology.